SjS patients with anti-NuMA antibodies presented fewer ocular sicca syndrome and dryness complications and anti-Ro/SSA and/or anti-La/SSB antibodies were less frequently present. This evidence concerns the gene TRIM21 and Schwartz-Jampel syndrome.